Friday 19 April 2024
Internal Reference Number: FOI_6331
Date Request Received: 20/10/2021 00:00:00
Date Request Replied To: 17/11/2021 00:00:00
This response was sent via: By Email
Request Summary: Treatment for colorectal cancer
Request Category: Researcher
| Question Number 1: Within your health trust, how many patients have been treated in the past 3 months with the following agents for colorectal cancer [CRC]? • Aflibercept • Bevacizumab • Capecitabine • CAPIRI • CAPOX (XELOX) • Cetuximab in combination with FOLFIRI • Cetuximab in combination with FOLFOX • Cetuximab not in combination with FOLFIRI or FOLFOX • Irinotecan only • FOLFIRI • FOLFOX • Fluorouracil (5FU) only • Oxaliplatin only • Panitumumab in combination with FOLFIRI • Panitumumab in combination with FOLFOX • Panitumumab not in combination with FOLFIRI or FOLFOX • Pembrolizumab • Nivolumab • Raltitrexed • Ramucirumab • Regorafenib • Sorafenib • Other SACT | |
| Answer To Question 1: Aflibercept, bevacizumab, CAPIRI, Cetuximab with FOLFIRI, irinotecan only and the one with oxaliplatin, fluorouracil, oxaliplatin only, panitumumab not in combination, nivolumab, ramucirumab, regorafenib and sorafenib all zero Capecitabine -7 CAPOX 27 Cetuximab not in combination with FOLFOX or FOLFIRI- 2 patients FOLFIRI- 7 FOLFOX- 14 Panitumumab with FOLFIRI- 3 Panitumumab with FOLFOX- 1 Pembrolizumab- 2 Raltirexed- 1 Unable to supply data for for Other SACT as there were too many treatment episodes to filter to estimate the number | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
